Servier India introduces ‘Ivosidenib’ (Tibsovo®), in India, First-in-class Targeted Therapy in Oncology
Chennai, June 2025 Servier India, a subsidiary of the leading French pharmaceutical Servier Group, announced the launch of Ivosidenib (Tibsovo®), an oral targeted therapy approved in the management of cancer patients with Acute Myeloid Leukemia (AML) and…













































